Public Demo

Live MediSum Demo

Starting with Cardiology -> Interventional Cardiology. Use the controls below to choose a specialty, subspecialty, procedure, domain, or topic. If an exact lane has limited supply, the demo broadens to the closest supported real PubMed-linked records and says so.

DefaultSpineOrthopedic SurgeryArthroplastySports MedicineCardiologyInterventionalPreventive

Interactive Sample

Sample: Cardiology -> Interventional Cardiology

Choose your specialty and subspecialty, then refine by procedure, domain, or topic of interest.

Open route

1. Specialty

2. Subspecialty

3. Procedure, Domain, Topic

3 PubMed-linked demo samples

Requested demo lane: Cardiology -> Interventional Cardiology. Current output: Cardiology -> Interventional Cardiology.

Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry.

JAMAApril 13, 2026PMID: 41973411

Makkar, Raj R RR; Gupta, Aakriti A; O'Neill, Brian P BP; et al.

In 1017 successful TTVR implants from 1034 attempts across 82 US centers, 30-day outcomes showed high procedural success with near-complete TR reduction, 3.1% mortality, low stroke (0.2%) and heart-failure hospitalization (3.1%), improvements in NYHA class and KCCQ-OS scores, and no significant outcome differences by baseline CIED status, supporting safety and effectiveness in real-world practice.

CardiologyStructural HeartInterventional CardiologyTricuspid InterventionPatient Selection & Outcomes (TAVR/TMVR registries)
Open in PubMed

Impella Protected Percutaneous Coronary Intervention Outcomes Compared with Intra-Aortic Balloon Pump: A Contemporary View.

American Journal of CardiologyApril 2, 2026PMID: 41935767

Panoulas, Vasileios V; Schreiber, Theodore T; Tsintzos, Stelios S; et al.

Pooled analysis of PROTECT-II and PROTECT-III trials using the win ratio in 930 patients (719 Impella, 211 IABP) showed superior 90-day outcomes for Impella versus IABP (win ratio 1.691; p<0.001) across a hierarchical MACCE endpoint, with consistent benefits in complex cases and improved metrics after excluding early ‘‘learning’’ cases. Results suggest Impella-supported high-risk PCI provided net clinical benefit over IABP through 90 days.

CardiologyInterventional CardiologyPCIACS Intervention StrategiesRandomized & Interventional Trials
Open in PubMed

Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis.

JACCApril 2, 2026PMID: 41984017

Cutlip, Donald E DE; Mehran, Roxana R; Sharma, Samin S; et al.

In the SELUTION4ISR randomized trial of 418 patients with coronary in-stent restenosis, the sirolimus-eluting balloon (DEB) was noninferior to usual-care control (predominantly repeat DES) for target lesion failure at 12 months, but DEB was not noninferior to DES when comparing single-layer ISR; outcomes varied by operator-selected control with DEB performing worse than DES but better than balloon angioplasty alone.

CardiologyInterventional CardiologyPCIImaging-Guided PCI (IVUS, OCT)Randomized & Interventional Trials
Open in PubMed